Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 15 (10), 2359-2377

Vaccines Against Ebola Virus and Marburg Virus: Recent Advances and Promising Candidates

Affiliations
Review

Vaccines Against Ebola Virus and Marburg Virus: Recent Advances and Promising Candidates

John J Suschak et al. Hum Vaccin Immunother.

Abstract

The filoviruses Ebola virus and Marburg virus are among the most dangerous pathogens in the world. Both viruses cause viral hemorrhagic fever, with case fatality rates of up to 90%. Historically, filovirus outbreaks had been relatively small, with only a few hundred cases reported. However, the recent West African Ebola virus outbreak underscored the threat that filoviruses pose. The three year-long outbreak resulted in 28,646 Ebola virus infections and 11,323 deaths. The lack of Food and Drug Administration (FDA) licensed vaccines and antiviral drugs hindered early efforts to contain the outbreak. In response, the global scientific community has spurred the advanced development of many filovirus vaccine candidates. Novel vaccine platforms, such as viral vectors and DNA vaccines, have emerged, leading to the investigation of candidate vaccines that have demonstrated protective efficacy in small animal and nonhuman primate studies. Here, we will discuss several of these vaccine platforms with a particular focus on approaches that have advanced into clinical development.

Keywords: Ebola virus; Marburg virus; filovirus; vaccines.

Similar articles

See all similar articles

Cited by 1 article

Publication types

Grant support

This work was supported by the Defense Threat and Reduction Agency [CB10204].

LinkOut - more resources

Feedback